XML 25 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue
 6 Months Ended
Jun. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Our disaggregated revenues were as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Royalties$124,918 $111,740 $245,511 $211,380 
Product sales, net
Proprietary product sales
44,139 32,293 79,394 60,254 
Bulk rHuPH20 sales
24,634 27,133 35,144 49,202 
Device partnered product sales
10,113 14,463 22,931 25,227 
Total product sales, net78,886 73,889 137,469 134,683 
Revenues under collaborative agreements
Event-based development and regulatory milestones and other fees
25,500 33,000 39,500 33,000 
Device licensing and development revenue
2,049 2,409 4,752 4,118 
Total revenues under collaborative agreements27,549 35,409 44,252 37,118 
Total revenues$231,353 $221,038 $427,232 $383,181 
During the three months ended June 30, 2024, we recognized revenue related to licenses granted to partners in prior periods in the amount of $150.4 million. This amount represents royalties earned in the current period in addition to $25.5 million of variable consideration in the contracts where uncertainties were resolved and the development milestones are expected to be achieved or were achieved. We also recognized revenue of $0.5 million during the three months ended June 30, 2024 that had been included in accrued expense and other long-term liabilities in our condensed consolidated balance sheets as of December 31, 2023.
During the six months ended June 30, 2024, we recognized revenue related to licenses granted to partners in prior periods in the amount of $285.0 million. This amount represents royalties earned in the current period in addition to $39.5 million of variable consideration in the contracts where uncertainties were resolved and the development milestones are expected to be achieved or were achieved. We also recognized revenue of $0.6 million during the six months ended June 30, 2024 that had been included in accrued expense and other long-term liabilities in our condensed consolidated balance sheets as of December 31, 2023.
Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands):
June 30, 2024December 31, 2023
Accounts receivable, net$210,416 $233,254 
Other contract assets4,108 956 
Deferred revenues4,856 4,048 
As of June 30, 2024, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $89.2 million, of which $84.3 million relates to unfulfilled product purchase orders and $4.9 million has been collected and is reported as accrued expense and other long-term liabilities in our condensed consolidated balance sheets. The unfulfilled product purchase orders are estimated to be delivered by the end of 2025. Of the total deferred revenues of $4.9 million, $1.3 million is expected to be used by our customers within the next 12 months.
We recognized contract assets of $4.1 million as of June 30, 2024, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.